Saturday, September 6, 2025
  • Advertise
  • Recruitment
  • Contact us:
  • Register
Irish Pharmacy News
  • News
    • Latest
    • Community Pharmacy
  • Learning
    • CPD
    • Features
    • Team Training
    • Research
  • Magazines
  • OTC
    • OTC Awards
    • Product News
  • Awards
    • Irish Pharmacy Awards 2024
    • Awards News
  • HPN
  • Log In
  • Register
No Result
View All Result
  • News
    • Latest
    • Community Pharmacy
  • Learning
    • CPD
    • Features
    • Team Training
    • Research
  • Magazines
  • OTC
    • OTC Awards
    • Product News
  • Awards
    • Irish Pharmacy Awards 2024
    • Awards News
  • HPN
  • Log In
  • Register
No Result
View All Result
Irish Pharmacy News

UK’s NICE approves new injection medication for chronic migraine patients

Natalie by Natalie
29 April 2020
in Developments, Product News
0
  • Medication currently under review for approval for use in Irish patients
    • 1 in 7 people[1] suffer from migraines in the Republic of Ireland – a condition which impacts as many as 700,000 people[2]

The UK’s National Institute for Health and Care Excellence (NICE) has recommended a new migraine medication for use by chronic migraine patients6.

The National Institute for Health and Care Excellence (NICE) has recommended AJOVY®     (fremanezumab) for the prophylaxis of migraine in adults with chronic migraine who have not responded to at least three prior preventive treatments.

AJOVY® belongs to a class of medications called anti-CGRPs, which have been specifically designed to target the underlying causes of migraine.

The medicine can be self-injected either monthly or quarterly, once patients are trained by a Healthcare Professional3.

Current migraine prevention therapies include anti-epileptics, anti-depressants, beta blockers or onabotulinumtoxinA injections, however these were not developed specifically to target migraine4.

The majority of migraine sufferers have Migraine without Aura – common symptoms being an intense throbbing headache, usually on one side of the head, worsened by movement, and lasting from 4-72 hours5.  Other symptoms can include nausea, vomiting, sensitivity to light, noises and smells, stiffness of the neck and shoulders and blurred vision5

Research has shown that 1 in 71 people suffer from migraines in the Republic of Ireland – a condition which impacts as many as 700,0002 people overall.

In the Republic of Ireland, AJOVY® is currently being reviewed for use by the National Centre for Pharmacoeconomics (NCPE).

Previous Post

Clonmel Healthcare is delighted to announce the launch of Cinacalcet Clonmel 30mg, 60mg and 90mg Film-coated Tablets.

Next Post

Blood clotting a significant cause of death in patients with COVID-19

Next Post

Blood clotting a significant cause of death in patients with COVID-19

Four UCD researchers receive ERC Starting Grants for groundbreaking research projects

Four UCD researchers receive ERC Starting Grants for groundbreaking research projects

4 September 2025
EUROPEAN COMMISSION AUTHORISES TWICE-YEARLY LENACAPAVIR FOR HIV  PREVENTION (brand name YEYTUO®) 

EUROPEAN COMMISSION AUTHORISES TWICE-YEARLY LENACAPAVIR FOR HIV  PREVENTION (brand name YEYTUO®) 

4 September 2025
Back to school: Expert guidance from the HSE for a smoother start to the school year

Back to school: Expert guidance from the HSE for a smoother start to the school year

22 August 2025

RECOMMENDED NEWS

St Francis Hospice Dublin and All Ireland Institute for Hospice and Palliative Care (AIIHPC) today officially launched a new eLearning programme to teach secondary school pupils in Ireland about palliative care and the role of hospices in helping people with life limiting illnesses to achieve the best quality of life possible.

Palliative Care eLearning Programme for Secondary Students Launched during Palliative Care Week

3 years ago
McCabes Pharmacy continue to grow with three new store acquisitions…

McCabes Pharmacy continue to grow with three new store acquisitions…

2 years ago

Poll Exclusive: how prepared are Irish pharmacies for the FMD deadline next February?

7 years ago
Scope adds two new products to its portfolio and rebrands heritage product

Scope adds two new products to its portfolio and rebrands heritage product

5 years ago
Tweets by Irish_PharmNews

Quick links

  • About
  • Advertise
  • Careers
  • Contact us

Other info

  • Contact us
  • Register for Digital Magazines
  • Privacy Policy
  • About
  • Advertise
  • Careers
  • Contact us

© 2024 IPN

  • Login

    Forgot password? | Register

    Register

    Registration confirmation will be emailed to you.

    Login | Forgot password?

    Reset Password

    Please enter your username or email address. You will receive a link to create a new password via email.

    Login

Login

Register

Forgotten Password?

Register | Lost your password?
| Back to Login
No Result
View All Result
  • News
  • Learning
  • Other
    • Conferencing
    • Developments
    • Product News
    • Profiles
    • Research
  • Digital Magazines (IPN Online Issues Older Issue Tabs)
  • Awards

© 2024 IPN